New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
07:36 EDTFLMLFlamel announces positive results of FIM clinical trial with Micropump
Flamel Technologies announced that its First-in-Man, or FIM, clinical study in healthy volunteers using its proprietary Micropump technology applied to sodium oxybate has identified formulations that demonstrate the potential to eliminate the second nighttime dose for patients suffering from narcolepsy achieved the objective of one single dose before bedtime for patients suffering from narcolepsy, eliminating the need for a second dose. The current dosing regimen for the standard of care, Xyrem, in the United States is two equal, divided doses: the first dose at bedtime and the second dose 2.5 to 4 hours later. The elimination of the second dose for narcolepsy patients would not only provide more convenience, but may improve the benefit sodium oxybate provides as there will be no disruption to nighttime sleep. The potential for additional benefits, including improved safety, will be studied.
News For FLML From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
08:43 EDTFLMLFlamel acquisition positive, says JMP Securities
Subscribe for More Information
07:28 EDTFLMLFlamel acquisition positive, says SunTrust
Subscribe for More Information
February 8, 2016
16:03 EDTFLMLFlamel acquires FSC Pediatrics
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use